|
1）Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-9
|
|
|
|
2）日本肝移植研究会．肝移植症例登録報告．移植．2014; 49: 261-74
|
|
|
|
|
3）Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25: 310-2
|
|
|
|
|
|
4）Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007; 25: 299-302
|
|
|
|
|
|
5）Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis. 2007; 25: 313-9
|
|
|
|
|
|
6）Todo S, Furukawa H, Tada M, et al. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2007; 13(11 Suppl 2): S48-54
|
|
|
|
|
|
7）Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008; 14: 935-45
|
|
|
|
|
|
8）Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009; 87: 531-7
|
|
|
|
|
|
9）嶋村 剛，藤堂 省．脈管浸潤からみた肝移植成績．肝胆膵．2013; 66: 967-79
|
|
|
|
|
|
10）Moon DB, Lee SG, Hwang S, et al. Should Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Be Contraindicated for Living Donor Liver Transplantation? Transplantation. 2015; 99: S224
|
|
|
|
|
|
11）Bhangui P, Dhir U, Piplani T, et al. Should Segmental Portal Vein Tumor Thrombosis Be an Absolute Contraindication for Liver Transplantation in Patients With Hepatocellular Carcinoma? Transplantation. 2015; 99: S284
|
|
|
|
|
|
12）Lee HW, Suh KS, Song GW, et al. Liver Transplantation for Far Advanced Hepatocellular Carcinoma: Korean Multicenter Study. Transplantation. 2015; 99: S121
|
|
|
|
|
|
13）Toso C, Mentha G, Kneteman NM, et al. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010; 52: 930-6
|
|
|
|
|
|
14）Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014; 97 Suppl 8: S10-7
|
|
|
|
|
|
15）Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009; 49: 832-8
|
|
|
|
|
|
16）Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48: 819-27
|
|
|
|
|
|
17）Axelrod D, Koffron A, Kulik L, et al. Living donor liver transplant for malignancy. Transplantation. 2005; 79: 363-6
|
|
|
|
|
|
18）Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10: 35-43
|
|
|
|
|
|
19）Saemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant. 2009; 9: 2655-61
|
|
|
|
|
|
20）Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation. 2010; 89: 227-31
|
|
|
|
|
|
21）Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2013; 37: 411-9
|
|
|
|
|
|
22）Cholongitas E, Mamou C, Rodriguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014; 27: 1039-49
|
|
|
|
|
|
23）Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC cancer. 2010; 10: 190
|
|
|
|
|
|
24）Taketomi A, Fukuhara T, Morita K, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010; 17: 2283-9
|
|
|
|
|
|
25）Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90
|
|
|
|
|
|
26）Zavaglia C, Airoldi A, Mancuso A, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013; 25: 180-6
|
|
|
|
|
|
27）Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012; 18: 45-52
|
|
|
|
|
|
28）Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol. 2013; 59: 59-66
|
|
|
|
|
|
29）Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol. 2013; 59: 3-5
|
|
|
|
|
|
30）Mancuso A, Airoldi A, Vigano R, et al. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis. 2011; 43: 754
|
|
|
|
|
|
31）Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57: 821-9
|
|
|
|
|
|
32）Sposito C, Mazzaferro V. Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue". J Hepatol. 2014; 60: 682-3
|
|
|
|
|